Wright R D, Krauss J S
Department of Pathology, Medical College Georgia Hospital, Augusta 30912-3620.
Ann Clin Lab Sci. 1990 Jan-Feb;20(1):73-8.
Plasma drawn from 22 patients with a broad range of von Willebrand factor (vWF) levels, including one patient with rare, severe type III von Willebrand's disease, was used to investigate the adaptability of the Bio/Data Corp. vW Factor Assay, a ristocetin cofactor-based kit developed for use with a platelet aggregometer, to a macroscopic platelet agglutination technique. The results were compared to those obtained using the General Diagnostics von Willebrand Factor Assay, another ristocetin cofactor-based kit developed for use as a macroscopic platelet agglutination procedure. No significant difference (p greater than 0.5) existed between results obtained by these two kits. The mean and standard deviation of the vWF levels (as percent of normal) were 132 +/- 66.7 by the General Diagnostics kit and 133 +/- 59.0 by the Bio/Data Corp. kit. The correlation coefficient (r) was 0.81. The Bio/Data Corp. kit is more costly per test than the General Diagnostics kit. However, it was shown to be compatible with the macroscopic agglutination technique and required no modification to be used in that manner.
从22名血管性血友病因子(vWF)水平范围广泛的患者中采集血浆,其中包括1名患有罕见严重III型血管性血友病的患者,用于研究Bio/Data Corp. vW因子检测法的适应性。该检测法是一种基于瑞斯托霉素辅因子的试剂盒,专为与血小板聚集仪配合使用而开发,采用宏观血小板凝集技术。将结果与使用通用诊断血管性血友病因子检测法得到的结果进行比较,后者是另一种基于瑞斯托霉素辅因子的试剂盒,专为宏观血小板凝集程序而开发。这两种试剂盒得到的结果之间不存在显著差异(p大于0.5)。通用诊断试剂盒测得的vWF水平(以正常水平的百分比表示)的平均值和标准差为132±66.7,Bio/Data Corp.试剂盒测得的为133±59.0。相关系数(r)为0.81。Bio/Data Corp.试剂盒每次检测的成本高于通用诊断试剂盒。然而,已证明它与宏观凝集技术兼容,以这种方式使用无需进行修改。